IP Library Granted Patent US 9,132,071
Granted Patent B2
US 9,132,071 · App. 12/010,778 · Granted Sep 15, 2015

Compositions containing quaternary ammonium compounds

Inventors: Laura Rabinovich-Guilatt (Kadima, IL); Gregory Lambert (Chatenay Malabry, FR); Frederic Lallemand (Fresnes, FR); Betty Philips (Antony, FR)
Assignee: SANTEN SAS
A61K8/06A61K8/062A61K8/416A61K9/0048A61Q17/005A61Q19/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,071
App. No.
12/010,778
Granted
Sep 15, 2015
Kind
B2
Abstract

Compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, where composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, and the ophthalmic emulsions being are useful for eye care or for the treatment of eye conditions.

Claims (27)

1. An emulsion, comprising:

an aqueous phase comprising water; and

0.0005% to 0.1% by weight of the total emulsion of at least one alkyl (C12-C16) dimethyl- or trimethyl-benzyl ammonium halide, wherein at least 20% by weight of the ammonium halide is a C16-alkyl dimethyl- or trimethyl-benzyl ammonium halide

and wherein the emulsion droplets have a zeta potential of at least +14.3 mV, and the emulsion remains stable for at least three months after emulsification.

2. The emulsion according to claim 1 , wherein the emulsion is an oil-in-water emulsion.

3. The emulsion according to claim 1 , wherein at least 80% by weight of the ammonium halide is a C 16 -alkyl dimethyl- or trimethyl-benzyl ammonium halide.

4. The emulsion according to claim 1 , wherein about 90% by weight of the ammonium halide is a C16-alkyl dimethyl- or trimethyl-benzyl ammonium halide.

5. The emulsion according to claim 1 , wherein about 95% by weight of the ammonium halide is a C16-alkyl dimethyl- or trimethyl-benzyl ammonium halide.

6. The emulsion according to claim 1 , wherein the alkyl (C12-C16) dimethyl- or trimethyl-benzyl ammonium halide is cetalkonium chloride.

7. The emulsion according to claim 1 , comprising about 0.002% to about 0.01% by weight of the at least one alkyl (C12-C16) dimethyl- or trimethyl-benzyl ammonium halide.

8. The emulsion according to claim 1 , wherein the emulsion includes an oily phase comprising at least one compound selected from the group consisting of triglycerides, medium chain triglycerides, long chain triglycerides, modified propylene glycol, propylene glycol diester, mineral oil, heavy mineral oil, light mineral oil, vegetable oil, castor oil, olive oil, corn oil, soya oil, peanut oil, cottonseed oil, coconut oil, palm oil, almond oil, and sesame oil.

9. The emulsion according to claim 1 , wherein the emulsion includes an oily phase comprising medium chain triglycerides.

10. The emulsion according to claim 1 , wherein the emulsion comprises at least one surfactant selected from the group consisting of lecithins, sodium docusate, sodium lauryl sulphate, poloxamers, polyoxyethylene sorbitan fatty acids, polyoxyethylene castor oils derivatives, tyloxapol, and polyoxyethylene alkyl ethers.

11. The emulsion according to claim 1 , wherein the emulsion comprises at least one osmotic agent.

12. The emulsion according to claim 1 , wherein the emulsion further comprises at least one additional cationic agent.

13. The emulsion according to claim 1 , wherein the alkyl (C12-C16) dimethyl- or trimethyl-benzyl ammonium halide is the only cationic agent that is included in the emulsion.

14. The emulsion according to claim 1 , wherein the emulsion further comprises an active substance selected from the group consisting of riluzole, fusidic acid, latanoprost, loratadine, tacrolimus, naphazoline and ketanserine.

15. An ophthalmic oil-in-water emulsion, comprising:

an aqueous phase comprising water;

0.0005% to 0.1% by weight of the total emulsion of at least one alkyl (C12-C16) dimethyl- or trimethyl-benzyl ammonium halide, wherein at least 20 by weight of the ammonium halide is a C16-alkyl dimethyl- or trimethyl-benzyl ammonium halide;

an oily phase; and

a surfactant,

and wherein emulsion droplets have a zeta potential of at least +14.3 mV, and the emulsion remains stable for at least three months after emulsification.

16. The emulsion according to claim 15 , wherein at least 80% by weight of the ammonium halide is a C16-alkyl dimethyl- or trimethyl-benzyl ammonium halide.

17. The emulsion according to claim 15 , wherein the alkyl (C12-C16) dimethyl- or trimethyl-benzyl ammonium halide is cetalkonium chloride.

18. The emulsion according to claim 15 , wherein the oily phase comprises at least one compound selected from the group consisting of triglycerides, medium chain triglycerides, long chain triglycerides, modified propylene glycol, propylene glycol diester, mineral oil, heavy mineral oil, light mineral oil, vegetable oil, castor oil, olive oil, corn oil, soya oil, peanut oil, cottonseed oil, coconut oil, palm oil, almond oil, and sesame oil.

19. The emulsion according to claim 15 , wherein the aqueous phase comprises at least 99.9% water.

Assignments (3)
CHANGE OF ADDRESS Recorded Feb 20, 2025
From: SANTEN
To: SANTEN
Reel/Frame 070276/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2013
From: NOVAGALI PHARMA SA
To: SANTEN SAS
Reel/Frame 031667/0321 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2008
From: RABINOVICH-GUILATT, LAURA; LAMBERT, GREGORY; LALLEMAND, FREDERIC; PHILIPS, BETTY
To: NOVAGALI PHARMA SA
Reel/Frame 020865/0510 →
Priority Claims (1)
EP 06291236 · Jul 28, 2006 · regional
Continuity (2)
Continuation In Part 11494493 · Jul 28, 2006
Related Publication 20080194532A1 · Aug 14, 2008